The emerging role of aquaporin 5 (AQP5) expression in systemic malignancies.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Aquaporins in Respiratory System.Advances in experimental medicine and biology · 2023
   Article
2. Effects of AQP5 gene silencing on proliferation, migration and apoptosis of human glioma cells through regulating EGFR/ERK/ p38 MAPK signaling pathway.Oncotarget · 2017
   Article
3. Effect of AQP9 Expression in Androgen-Independent Prostate Cancer Cell PC3.International journal of molecular sciences · 2016
   Article
4. Aquaporins as diagnostic and therapeutic targets in cancer: how far we are?Journal of translational medicine · 2015
   Review

Corrections and comments

• Comment on
  AQP5 silencing suppresses p38 MAPK signaling and improves drug resistance in colon cancer cells.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as